References
M20-371 (AbbVie)
Study Drug: ABBV-154
Study Drug administration: IV and Subcutaneous Injection
Principal Investigator: Jay Desai
Disease: Moderate to Severe Crohn’s Disease
Inclusion criteria: endoscopically and clinically active CD, failed biologics (biologic therapy include TNF antagonists, vedolizumab, ustekinumab)
Exclusion criteria: current fistulizing disease, abscess, ostomy or ileoanal pouch, bowel resection within last 3 months, positive for C Difficile, Hepatitis B or C, HIV
Status: Upcoming
EMERALD-1 (Morphic Therapeutic)
Study Drug: MORF-057
Study Drug administration: Oral
Principal Investigator: Jay Desai
Disease: Moderate to Severe Ulcerative Colitis
Inclusion criteria: endoscopically and clinically active UC, treatment naïve OR failed biologics (include TNF antagonists, vedolizumab, ustekinumab), corticosteroids, immunomodulators, or treatment naïve
Exclusion criteria: abscesses, strictures, ileostomy, colostomy, positive for C. Difficile, HIV, Hepatitis B or Hepatitis C
Status: Enrolling